Seer (NASDAQ:SEER) Stock Price Up 1.1% – Still a Buy?

Seer, Inc. (NASDAQ:SEER)’s share price traded up 1.1% during mid-day trading on Monday . The stock traded as high as $1.8450 and last traded at $1.84. 48,443 shares traded hands during trading, a decline of 75% from the average session volume of 191,270 shares. The stock had previously closed at $1.82.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. Wall Street Zen upgraded shares of Seer to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Seer in a report on Wednesday, October 8th. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company presently has a consensus rating of “Sell”.

Seer Stock Performance

The stock has a market capitalization of $102.65 million, a price-to-earnings ratio of -1.35 and a beta of 1.60. The business has a fifty day simple moving average of $1.95 and a 200 day simple moving average of $2.07.

Seer (NASDAQ:SEER) last posted its earnings results on Thursday, November 6th. The company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.01. The company had revenue of $4.12 million during the quarter, compared to the consensus estimate of $4.00 million. Seer had a negative return on equity of 25.88% and a negative net margin of 484.51%. On average, sell-side analysts forecast that Seer, Inc. will post -1.42 earnings per share for the current fiscal year.

Insider Transactions at Seer

In other Seer news, CEO Omid Farokhzad sold 33,838 shares of the business’s stock in a transaction dated Wednesday, November 19th. The shares were sold at an average price of $1.97, for a total value of $66,660.86. Following the completion of the sale, the chief executive officer owned 1,238,230 shares of the company’s stock, valued at $2,439,313.10. The trade was a 2.66% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 11.28% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Seer

Hedge funds and other institutional investors have recently made changes to their positions in the business. Jacobs Levy Equity Management Inc. boosted its stake in shares of Seer by 124.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 363,355 shares of the company’s stock valued at $614,000 after buying an additional 201,491 shares during the period. Bridgeway Capital Management LLC increased its stake in Seer by 15.5% during the 2nd quarter. Bridgeway Capital Management LLC now owns 837,443 shares of the company’s stock worth $1,792,000 after acquiring an additional 112,100 shares during the period. XTX Topco Ltd acquired a new position in Seer in the 2nd quarter valued at $172,000. Geode Capital Management LLC lifted its position in shares of Seer by 16.5% during the 2nd quarter. Geode Capital Management LLC now owns 509,727 shares of the company’s stock valued at $1,091,000 after acquiring an additional 72,265 shares during the period. Finally, Jane Street Group LLC lifted its position in shares of Seer by 33.3% during the 1st quarter. Jane Street Group LLC now owns 254,174 shares of the company’s stock valued at $430,000 after acquiring an additional 63,432 shares during the period. 75.20% of the stock is currently owned by institutional investors and hedge funds.

About Seer

Seer, Inc is a life sciences company focused on pioneering next-generation proteomics, the large-scale study of proteins and their functions in complex biological systems. By leveraging proprietary nanoparticle-based technology, Seer’s platform enables high-throughput, unbiased protein analysis from biological samples, addressing a critical bottleneck in drug discovery, biomarker research and precision medicine.

The company’s flagship Proteograph Product Suite combines engineered nanoparticle assays with advanced mass spectrometry and bioinformatics pipelines to deliver deep proteomic coverage in a scalable workflow.